Anticoagulant therapy for percutaneous coronary intervention

Circ Cardiovasc Interv. 2010 Feb 1;3(1):80-8. doi: 10.1161/CIRCINTERVENTIONS.109.884478.
No abstract available

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Angioplasty, Balloon, Coronary / adverse effects*
  • Anticoagulants / pharmacology*
  • Anticoagulants / therapeutic use
  • Antithrombins / pharmacology
  • Antithrombins / therapeutic use
  • Clinical Trials as Topic
  • Coronary Thrombosis / drug therapy
  • Coronary Thrombosis / etiology*
  • Endothelium, Vascular / drug effects*
  • Endothelium, Vascular / metabolism
  • Endothelium, Vascular / pathology
  • Endothelium, Vascular / surgery
  • Enoxaparin / pharmacology
  • Enoxaparin / therapeutic use
  • Fibrinolytic Agents / pharmacology
  • Fibrinolytic Agents / therapeutic use
  • Fondaparinux
  • Hirudins / pharmacology
  • Humans
  • Myocardial Ischemia
  • Peptide Fragments / pharmacology
  • Peptide Fragments / therapeutic use
  • Platelet Activation / drug effects
  • Polysaccharides / pharmacology
  • Polysaccharides / therapeutic use
  • Postoperative Complications*
  • Recombinant Proteins / pharmacology
  • Recombinant Proteins / therapeutic use
  • Thrombin / genetics
  • Thrombin / immunology
  • Thrombin / metabolism

Substances

  • Anticoagulants
  • Antithrombins
  • Enoxaparin
  • Fibrinolytic Agents
  • Hirudins
  • Peptide Fragments
  • Polysaccharides
  • Recombinant Proteins
  • Thrombin
  • Fondaparinux
  • bivalirudin